Sabel Michael S, Liu Yashu, Lubman David M
Department of Surgery, University of Michigan Health Systems, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
Int J Proteomics. 2011;2011:181890. doi: 10.1155/2011/181890. Epub 2011 Oct 11.
The present clinical staging of melanoma stratifies patients into heterogeneous groups, resulting in the application of aggressive therapies to large populations, diluting impact and increasing toxicity. To move to a new era of therapeutic decisions based on highly specific tumor profiling, the discovery and validation of new prognostic and predictive biomarkers in melanoma is critical. Genomic profiling, which is showing promise in other solid tumors, requires fresh tissue from a large number of primary tumors, and thus faces a unique challenge in melanoma. For this and other reasons, proteomics appears to be an ideal choice for the discovery of new melanoma biomarkers. Several approaches to proteomics have been utilized in the search for clinically relevant biomarkers, but to date the results have been relatively limited. This article will review the present work using both tissue and serum proteomics in the search for melanoma biomarkers, highlighting both the relative advantages and disadvantages of each approach. In addition, we review several of the major obstacles that need to be overcome in order to advance the field.
黑色素瘤目前的临床分期将患者分为异质性群体，导致对大量人群应用激进疗法，削弱了疗效并增加了毒性。为了迈向基于高度特异性肿瘤分析的治疗决策新时代，在黑色素瘤中发现和验证新的预后和预测生物标志物至关重要。基因组分析在其他实体瘤中显示出前景，但需要大量原发性肿瘤的新鲜组织，因此在黑色素瘤中面临独特挑战。出于这个原因以及其他原因，蛋白质组学似乎是发现新的黑色素瘤生物标志物的理想选择。蛋白质组学的几种方法已被用于寻找临床相关生物标志物，但迄今为止结果相对有限。本文将综述目前使用组织和血清蛋白质组学寻找黑色素瘤生物标志物的工作，突出每种方法的相对优缺点。此外，我们还综述了为推动该领域发展需要克服的几个主要障碍。
